Arizona State Retirement System Buys 914 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Arizona State Retirement System raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,500 shares of the company’s stock after acquiring an additional 914 shares during the period. Arizona State Retirement System’s holdings in Intellia Therapeutics were worth $717,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. MetLife Investment Management LLC lifted its position in shares of Intellia Therapeutics by 54.7% in the first quarter. MetLife Investment Management LLC now owns 37,362 shares of the company’s stock worth $2,715,000 after buying an additional 13,209 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Intellia Therapeutics by 2.7% during the 1st quarter. Rhumbline Advisers now owns 98,247 shares of the company’s stock worth $7,140,000 after acquiring an additional 2,620 shares in the last quarter. Cibc World Market Inc. raised its holdings in shares of Intellia Therapeutics by 47.3% during the 1st quarter. Cibc World Market Inc. now owns 4,740 shares of the company’s stock worth $344,000 after acquiring an additional 1,522 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Intellia Therapeutics by 11.9% during the 1st quarter. Blair William & Co. IL now owns 10,362 shares of the company’s stock valued at $753,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Intellia Therapeutics in the first quarter valued at $307,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

NTLA has been the subject of several research reports. Wedbush reiterated a “neutral” rating and set a $29.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, February 15th. Canaccord Genuity Group lifted their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Wolfe Research started coverage on Intellia Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Finally, The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $67.00.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $21.32 on Friday. Intellia Therapeutics, Inc. has a fifty-two week low of $21.18 and a fifty-two week high of $47.48. The company has a market capitalization of $2.05 billion, a PE ratio of -3.94 and a beta of 1.77. The company has a 50 day moving average price of $27.34 and a 200-day moving average price of $27.92.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. The business had revenue of ($1.92) million during the quarter, compared to analysts’ expectations of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period in the prior year, the business earned ($1.40) EPS. On average, analysts forecast that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.00% of the stock is owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.